KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next
Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance